Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*
Julien Carvelli(University of Reunion Island), Samuel Lehingue, Éric Vivier(Innate Pharma (France)), N. Schleinitz(Assistance Publique Hôpitaux de Marseille), Federico Rotolo(Sanofi (France)), Joyson Karakunnel(Parker Institute for Cancer Immunotherapy), Olivier Demaria(Innate Pharma (France)), Julien Viotti(Innate Pharma (France)), Lionel Velly(Centre National de la Recherche Scientifique), Michel Carlès(Centre Hospitalier Universitaire de Nice), Joanna Fares(Innate Pharma (France)), Frédéric Vely(Centre National de la Recherche Scientifique), Agnès Boyer-Chammard(Innate Pharma (France)), Pierre‐Yves Cordier(Hôpital Laveran), E. Le Dault(Hôpital Laveran), Karine Lacombe(Inserm), Christelle Pipéroglou(Centre National de la Recherche Scientifique), Jérôme Allardet-Servent(Hôpital Européen), Maxime Desgrouas(Centre hospitalier universitaire d'Orléans), Saber Davide Barbar(Université de Montpellier), Fabrice Camou(Hôpital Saint-André), Ferhat Meziani(Université de Strasbourg), Jean Dellamonica(Université Côte d'Azur), Megan Fraissé(Centre Hospitalier Victor Dupouy), Christophe Guervilly(Inserm), Luciana Batista(Innate Pharma (France))
Cited by 29
Related Papers
Functions of natural killer cells
|Nature Immunology|2008|3.8k
Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19
|JAMA|2020|2.4k
TLR3 Deficiency in Patients with Herpes Simplex Encephalitis
|Science|2007|1.1k
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
|JAMA Internal Medicine|2020|777
Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells
|Nature Immunology|2017|639